Back to VEEV
VEEV Stock: Growth, Valuation and Key Risks
$VEEVNEUTRALSoftware—Application

VEEV Stock: Growth, Valuation and Key Risks

Veeva combines recurring life-sciences software revenue with strong cash generation and recent earnings growth. At $301.53 as of Friday, November 13, the shares sit near the supplied analyst mean target, while premium valuation and the December 3 earnings report remain important considerations.

November 14, 202611 min read
Current Price
$301.53
-0.29%
Analyst Rating
Strong Buy
Price Target
$306.67
1.7% upside
P/E Ratio
48.56

Executive Summary

Investment Thesis: Veeva supplies cloud software to pharmaceutical, biotechnology and other life-sciences organizations, a specialized market where regulated workflows and customer data can create durable switching costs. Available figures show 17.6% revenue growth, 39.5% earnings growth, a 74.96% gross margin and substantial net cash, while the latest reported quarter beat its EPS estimate. Those operating strengths are balanced by a high earnings multiple, a share price close to the provided analyst mean target, and uncertainty ahead of the December 3 fiscal third-quarter report.

Current Price: $301.53 as of Friday, November 13 | Key Metric: 17.6% reported revenue growth | Stance: NEUTRAL

Veeva shares fell $0.89, or 0.29%, on Friday, the last US trading session before the weekend. US markets are closed Saturday, November 14, and are scheduled to reopen Monday, November 16. The neutral stance reflects a balance: business fundamentals appear healthy, but valuation and the limited gap between the share price and the supplied analyst consensus target temper the picture.

Company Overview

Veeva Systems develops cloud-based software and data products for the life-sciences industry. Its customers include pharmaceutical and biotechnology companies that use its applications for commercial operations, clinical research, regulatory processes and quality management. The specialized focus helps Veeva tailor products to complex workflows, though it also concentrates the business in one broad industry.

Key Products & Competitive Position

  • Core Business: Subscription software and data services for life-sciences companies, with revenue supported by enterprise deployments and ongoing customer usage.
  • Key Products: Veeva Vault applications serve areas such as clinical, regulatory and quality operations. Veeva CRM supports commercial teams, and the company is expanding its Vault CRM offering as customers evaluate platform options.
  • Competitive Moat: Industry-specific functionality, regulated-process expertise, customer relationships and the cost and operational risk involved in changing systems can support retention. These advantages are not absolute: customers can evaluate alternatives, and product transitions require careful execution.

Recent Developments

Veeva announced that it will report fiscal 2027 third-quarter results after the market closes on December 3, 2026. Its latest supplied earnings result, reported August 26, was $2.35 per share against a $2.23 estimate. Recent company commentary highlighted Vault CRM adoption and a diversified product portfolio as growth supports, while a Zacks article also cited market saturation as a risk to monitor. The supplied news items do not identify a new acquisition or a material change in strategy.

Financial Snapshot

Market Cap$48.82B
P/E Ratio48.56
52-Week Range$148.05 - $325.99
Dividend YieldNot provided
EPS (TTM)$6.25
ROE14.0%

Financial figures are drawn from the supplied company and market data. The additional Yahoo Finance extract reports TTM EPS of $6.08 and ROE of 14.43%, so data providers differ slightly in their measurement dates or calculations. The provided P/E of 48.56 is used here; at that multiple, investors are valuing Veeva well above many mature software businesses and are paying for continued growth and profitability.

Revenue & Earnings Trends

The additional financial data reports total revenue of approximately $3.46 billion, revenue growth of 17.6%, earnings growth of 39.5%, and net income of roughly $1.01 billion. Quarterly earnings growth is reported at 36.5%. These figures indicate that earnings have been growing faster than sales, an encouraging pattern if it reflects durable operating leverage rather than temporary factors. Gross margin is listed at 74.96% and profit margin at 29.34%, both consistent with a high-value software model.

Free cash flow is reported at approximately $1.26 billion, while operating cash flow is about $1.67 billion. Cash generation gives management flexibility to fund product development and operations. The provided figures do not include a detailed multi-year revenue table, so they don't establish whether the recent growth pace is accelerating or slowing over a longer period.

Balance Sheet Highlights

Veeva's reported current ratio of 5.46 and quick ratio of 5.36 indicate ample short-term liquidity. The additional extract lists $7.24 billion in cash, roughly $152 million in total debt and debt-to-equity of 2.04%. That implies a substantial net-cash position, which can cushion operating volatility and support investment, although cash alone doesn't determine whether the shares are attractively valued.

Valuation Analysis

Current Valuation Metrics

Forward P/E29.4Industry comparison not supplied
PEG Ratio1.17Growth-adjusted, provider reported
EV/EBITDA38.8Historical comparison not supplied
P/S Ratio14.1Peer comparison not supplied

Forward P/E, PEG and EV/EBITDA use the additional Yahoo Finance extract. P/S is an approximate calculation using the supplied $48.82 billion market capitalization and reported revenue of about $3.46 billion. The same data lists enterprise value to revenue at 12.07, a lower ratio than market-cap-to-sales because Veeva holds substantial net cash. Neither measure is inexpensive in isolation, and comparisons depend on peer growth, margins and accounting definitions.

Historical Comparison

A five-year average valuation was not provided, so a precise comparison with Veeva's own historical multiple isn't available. The supplied two-year average closing price is $236.02, below Friday's $301.53 close, but share-price history is not a substitute for historical valuation because earnings and expectations change over time. The stock's reported 52-week change is 3.09%, compared with 12.29% for the S&P 500 in the same extract, illustrating that the recent year has not been uniformly strong relative to the broad market.

Fair Value Estimate

The analyst target data supplied for this report gives a mean of $306.67 and a median of $310, equivalent to approximately 1.7% and 2.8% above Friday's close. The low and high estimates are widely dispersed at $165 and $400, respectively, signaling substantial disagreement. A separate Yahoo Finance extract lists a different mean target of $326.41, median of $325 and low target of $180, so target data varies by provider and analyst coverage set. These figures are estimates, not guarantees.

A valuation framework for Veeva needs to weigh its recurring revenue, high gross margins, cash generation and growth against its premium multiples and the possibility of slower expansion. A discounted cash flow estimate would be particularly sensitive to long-term revenue growth, operating margins and the discount rate. Without detailed forward cash-flow forecasts, a precise standalone fair value cannot be responsibly calculated from the supplied data; the current price appears to leave limited room to the provided consensus mean.

Competitive Landscape

Market Position

Market Share: Not provided, the relevant market is segmented by product | Ranking: A leading specialist in life-sciences cloud software, precise industry rank not provided

Key Competitors

Oracle (ORCL)Oracle offers enterprise cloud, database and industry software that can overlap with life-sciences workflows.
Salesforce (CRM)Salesforce provides customer relationship management platforms that compete in some commercial software use cases.
Medtronic (MDT) / other specialistsCompetition also comes from life-sciences software vendors and in-house systems; no single direct peer set was supplied.

These companies are broad reference points, not exact equivalents. Veeva's products are tailored to regulated life-sciences processes, while large enterprise software providers may compete for selected workflows, platform budgets or customer relationships.

Competitive Advantages

  • Industry expertise: Software designed for regulated processes can match customer needs more closely than general-purpose tools.
  • Switching costs: Replacing systems connected to validated workflows, data and employee processes can be complex, supporting customer retention when products perform well.
  • Product breadth: A portfolio spanning commercial and Vault applications can create opportunities to serve multiple needs within the same customer base.

Earnings Track Record

Last 4 Quarters: 1 documented beat / No documented misses. Three other quarter-by-quarter comparisons were not supplied, so this is not a complete four-quarter count.

Recent Earnings History

Q2 FY2027, reported Aug. 26$2.35 vs $2.23 estBEAT
Prior quarterActual and estimate not suppliedUNAVAILABLE
Earlier quarterActual and estimate not suppliedUNAVAILABLE
Earlier quarterActual and estimate not suppliedUNAVAILABLE

Guidance Trend

The supplied information includes an EPS estimate of $2.34 for the fiscal 2027 third quarter, scheduled for December 3, but no company-issued guidance range or history of revisions. The prior reported $2.35 EPS result exceeded the $2.23 estimate by $0.12, or about 5.4%. The upcoming report will help clarify whether customer demand, Vault CRM adoption and product diversification are translating into results consistent with market expectations.

Analyst Sentiment

Consensus Rating: Strong Buy, according to the supplied analyst tally

Strong Buy: 7Buy: 13Hold: 8Sell: 1Strong Sell: 0

The tally covers 29 analysts, with 20 at Buy or Strong Buy, eight at Hold and one at Sell. This is a third-party opinion snapshot, not a guarantee of performance or a recommendation in this report. The Yahoo Finance extract lists 27 analyst opinions and a different recommendation mean, which underscores that provider coverage and update timing can differ.

Price Targets

  • Low: $165
  • Mean: $306.67 (+1.7% upside based on the supplied target set)
  • High: $400

Recent Analyst Actions

No specific recent rating changes were included in the supplied data. The aggregate recommendation remains positive, but the mean target is close to the share price and individual targets range widely. Readers comparing services may encounter the alternative Yahoo Finance mean of $326.41; the analyst count and target set should be checked before drawing conclusions from that difference.

Recent News & Catalysts

Key Developments

  • Fiscal Q3 report scheduled: Veeva said it will release results for the quarter ended October 31, 2026, after the market closes on December 3. The supplied consensus EPS estimate is $2.34.
  • Latest reported earnings beat: On August 26, Veeva reported $2.35 EPS versus a $2.23 estimate. That beat is positive evidence for recent execution, though one quarter does not establish a continuing trend.
  • Vault CRM and product breadth: Recent coverage has pointed to expanding Vault CRM adoption and a diversified product portfolio as potential growth supports. Market saturation remains a counterpoint, and adoption pace and customer transitions warrant attention.

Upcoming Catalysts

Next Earnings: December 3, 2026, after market close | Key Events: Fiscal Q3 results and any updated outlook, evidence of Vault CRM adoption, subscription and customer growth trends, and commentary on demand and market saturation

Markets are closed on Saturday, November 14, and the next US trading session is Monday, November 16. The December results are the clearest company-specific near-term catalyst in the supplied calendar. Broad market volatility is also relevant: one news item described a sharp reversal in major US equity indexes after an early-November post-election rally, a reminder that software valuations can be sensitive to changes in risk appetite.

Technical Outlook

Current Price: $301.53 as of Friday, November 13 vs 52-Week High: $325.99 (-7.5% from high)

Trend Analysis

Friday's close was down 0.29% from the prior close of $302.42, within the day's $299.36 to $305.36 range. The share price is about 104% above the 52-week low of $148.05 and 7.5% below the high. The supplied two-year average close of $236.02 is below the current price, but there is not enough daily price, volume or moving-average information to establish a reliable short-term trend or momentum signal.

Key Levels

  • Resistance: Around $305, near Friday's intraday high, and $326, near the 52-week high
  • Support: Around $299, near Friday's intraday low, and $302, near the prior close; these are short-term reference points, not confirmed technical floors

Price levels are approximate observations based on the supplied range, not forecasts. A sustained move through a level would need confirmation from subsequent sessions and trading volume.

Bull vs Bear Case

Bull Case

  • Durable niche: Regulated life-sciences workflows and industry-specific software may support customer retention and recurring revenue.
  • Growth and cash generation: Reported revenue growth of 17.6%, earnings growth of 39.5% and free cash flow of about $1.26 billion provide evidence of a profitable growth model.
  • Product expansion: Wider Vault adoption and Vault CRM could broaden Veeva's role across customers if adoption proceeds effectively.

Bull Scenario Reference: $400, the high end of the supplied analyst target range, not a forecast

Bear Case

  • Premium valuation: A trailing P/E near 49 and EV/EBITDA near 39 leave the share price sensitive to slower growth or lower market multiples.
  • Execution and saturation: Product transitions, adoption pace and limited expansion in mature customer segments could constrain growth or create friction.
  • Target and macro uncertainty: The supplied mean target is close to the current price, targets span $165 to $400, and broader risk-off conditions could pressure growth stocks.

Bear Scenario Reference: $165, the low end of the supplied analyst target range, not a forecast

The target extremes represent analyst estimates and shouldn't be read as probability-weighted outcomes. What matters for a scenario assessment is whether operating results continue to justify the expectations embedded in the current valuation.

Risks to Consider

  • Valuation Risk: High multiples can amplify price reactions if growth, margins or guidance fall short of expectations. A strong balance sheet doesn't remove this risk.
  • Competitive Risk: Enterprise software providers, specialist vendors and internal systems can compete for customer budgets. Veeva must continue to differentiate its products and maintain customer confidence.
  • Macro Risk: Changes in interest rates, corporate technology spending and market risk appetite can affect valuation. The recent market volatility described in the news highlights the possibility of rapid sentiment shifts.
  • Execution Risk: Expanding Vault CRM and managing product adoption across regulated customers require reliable delivery and careful transitions. Slower adoption or disruption could weigh on growth.

Bottom Line

Investment Verdict: NEUTRAL

Veeva's reported growth, high margins, cash generation and latest earnings beat support a credible long-term operating case. At the same time, the stock's valuation is demanding, the supplied analyst mean target is only modestly above Friday's close, and the December 3 report could reset expectations. This is an informational assessment, not investment advice or a recommendation to buy, sell or hold any security.

Action Items for Investors

  • Long-term investors: Track customer retention, recurring revenue growth, product adoption and cash conversion over multiple quarters; these measures help test whether the business case is keeping pace with valuation.
  • Short-term traders: Note the December 3 earnings date and the approximate $299 to $326 technical reference range, while recognizing that earnings gaps and market volatility can overwhelm nearby levels.
  • Risk management: Compare the supplied analyst target set with other providers, confirm the date and definitions behind financial metrics, and consider how a slower-growth scenario would affect valuation. This is analytical context, not personalized advice.

What to Watch This Week

  • Trading after the weekend, beginning Monday, November 16, with particular attention to broader software-sector volatility.
  • Any company updates before the December 3 fiscal third-quarter report, especially those relevant to Vault CRM and customer adoption.
  • Changes in analyst estimates or target ranges, keeping in mind the conflicting target averages reported by data providers.

Data note: Market price and supplied recommendations are as of Friday, November 13, 2026. Financial provider extracts and analyst target sets differ in places; discrepancies are identified rather than reconciled with unsupported assumptions. This report is for informational purposes only and is not investment advice.

Share this report

Share this article

Spread the word on social media

Think VEEV will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.